October 21, 2024    Virogenbio announced that its investigational drug VG712 has been approved by the FDA to initiate a Phase I clinical trial for peripheral T-cell lymphoma (PTCL). Following its approval for cutaneous T-cell lymphoma (CTCL), this marks the second indication for VG712 in the field of T-cell malignancies, further validating its clinical potential to eliminate malignant T cells and restore anti-tumor immune function.